JP2001513653A - 新規な受容体 - Google Patents
新規な受容体Info
- Publication number
- JP2001513653A JP2001513653A JP51834899A JP51834899A JP2001513653A JP 2001513653 A JP2001513653 A JP 2001513653A JP 51834899 A JP51834899 A JP 51834899A JP 51834899 A JP51834899 A JP 51834899A JP 2001513653 A JP2001513653 A JP 2001513653A
- Authority
- JP
- Japan
- Prior art keywords
- receptor
- polynucleotide molecule
- protein
- seq
- molecule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 102000005962 receptors Human genes 0.000 claims abstract description 51
- 108020003175 receptors Proteins 0.000 claims abstract description 51
- 108091033319 polynucleotide Proteins 0.000 claims abstract description 37
- 102000040430 polynucleotide Human genes 0.000 claims abstract description 37
- 239000002157 polynucleotide Substances 0.000 claims abstract description 35
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 claims abstract description 15
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 claims abstract description 15
- 239000005557 antagonist Substances 0.000 claims abstract description 6
- 239000000556 agonist Substances 0.000 claims abstract description 5
- 230000000694 effects Effects 0.000 claims abstract description 5
- 239000012634 fragment Substances 0.000 claims description 29
- 239000002773 nucleotide Substances 0.000 claims description 14
- 125000003729 nucleotide group Chemical group 0.000 claims description 13
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 11
- 108090000623 proteins and genes Proteins 0.000 claims description 9
- 241000238631 Hexapoda Species 0.000 claims description 8
- 108020004999 messenger RNA Proteins 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 8
- 102000004169 proteins and genes Human genes 0.000 claims description 7
- 108020004414 DNA Proteins 0.000 claims description 5
- 150000001413 amino acids Chemical class 0.000 claims description 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 5
- 239000000523 sample Substances 0.000 claims description 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 4
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 claims description 4
- 108091034117 Oligonucleotide Proteins 0.000 claims description 4
- 210000003734 kidney Anatomy 0.000 claims description 4
- 241000699802 Cricetulus griseus Species 0.000 claims description 2
- 108091006027 G proteins Proteins 0.000 claims description 2
- 102000030782 GTP binding Human genes 0.000 claims description 2
- 108091000058 GTP-Binding Proteins 0.000 claims description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 2
- 230000000692 anti-sense effect Effects 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 239000013604 expression vector Substances 0.000 claims description 2
- 210000001672 ovary Anatomy 0.000 claims description 2
- 238000013519 translation Methods 0.000 claims description 2
- 230000009466 transformation Effects 0.000 claims 3
- 102000053602 DNA Human genes 0.000 claims 1
- 230000001747 exhibiting effect Effects 0.000 claims 1
- 239000013612 plasmid Substances 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 abstract description 4
- 210000004027 cell Anatomy 0.000 description 14
- 102000027582 GPCRs class B Human genes 0.000 description 5
- 108091008883 GPCRs class B Proteins 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 101710158332 Diuretic hormone Proteins 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 210000002216 heart Anatomy 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- 210000001685 thyroid gland Anatomy 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 230000003213 activating effect Effects 0.000 description 3
- 102220201851 rs143406017 Human genes 0.000 description 3
- 102100026439 Adhesion G protein-coupled receptor E1 Human genes 0.000 description 2
- 102100026423 Adhesion G protein-coupled receptor E5 Human genes 0.000 description 2
- 102100031836 Adhesion G-protein coupled receptor G2 Human genes 0.000 description 2
- 201000001321 Bardet-Biedl syndrome Diseases 0.000 description 2
- 108010022152 Corticotropin-Releasing Hormone Proteins 0.000 description 2
- 102000012289 Corticotropin-Releasing Hormone Human genes 0.000 description 2
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 2
- 108010083749 Glucagon-Like Peptide Receptors Proteins 0.000 description 2
- 102000006419 Glucagon-Like Peptide Receptors Human genes 0.000 description 2
- 239000000095 Growth Hormone-Releasing Hormone Substances 0.000 description 2
- 101000718225 Homo sapiens Adhesion G protein-coupled receptor E1 Proteins 0.000 description 2
- 101000718243 Homo sapiens Adhesion G protein-coupled receptor E5 Proteins 0.000 description 2
- 206010056715 Laurence-Moon-Bardet-Biedl syndrome Diseases 0.000 description 2
- 102100022831 Somatoliberin Human genes 0.000 description 2
- 101710142969 Somatoliberin Proteins 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 210000000918 epididymis Anatomy 0.000 description 2
- 201000010063 epididymitis Diseases 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 238000007901 in situ hybridization Methods 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 108060001064 Calcitonin Proteins 0.000 description 1
- 102000055006 Calcitonin Human genes 0.000 description 1
- 108010045403 Calcium-Binding Proteins Proteins 0.000 description 1
- 102000005701 Calcium-Binding Proteins Human genes 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 108010004460 Gastric Inhibitory Polypeptide Proteins 0.000 description 1
- 102100039994 Gastric inhibitory polypeptide Human genes 0.000 description 1
- 102000051325 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- 101800000224 Glucagon-like peptide 1 Proteins 0.000 description 1
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 1
- 102100031547 HLA class II histocompatibility antigen, DO alpha chain Human genes 0.000 description 1
- 101000866278 Homo sapiens HLA class II histocompatibility antigen, DO alpha chain Proteins 0.000 description 1
- 206010058359 Hypogonadism Diseases 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000036626 Mental retardation Diseases 0.000 description 1
- 230000004988 N-glycosylation Effects 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 102000003982 Parathyroid hormone Human genes 0.000 description 1
- 108090000445 Parathyroid hormone Proteins 0.000 description 1
- 102000014743 Pituitary Adenylate Cyclase-Activating Polypeptide Receptors Human genes 0.000 description 1
- 108010064032 Pituitary Adenylate Cyclase-Activating Polypeptide Receptors Proteins 0.000 description 1
- 102100040918 Pro-glucagon Human genes 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 201000007737 Retinal degeneration Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 108010086019 Secretin Proteins 0.000 description 1
- 102100037505 Secretin Human genes 0.000 description 1
- ZVNYJIZDIRKMBF-UHFFFAOYSA-N Vesnarinone Chemical compound C1=C(OC)C(OC)=CC=C1C(=O)N1CCN(C=2C=C3CCC(=O)NC3=CC=2)CC1 ZVNYJIZDIRKMBF-UHFFFAOYSA-N 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 102000030621 adenylate cyclase Human genes 0.000 description 1
- 108060000200 adenylate cyclase Proteins 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 208000025341 autosomal recessive disease Diseases 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000003491 cAMP production Effects 0.000 description 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
- 229960004015 calcitonin Drugs 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000001638 cerebellum Anatomy 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 210000003917 human chromosome Anatomy 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 102000035110 latrophilin Human genes 0.000 description 1
- 108091005543 latrophilin Proteins 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000000849 parathyroid Effects 0.000 description 1
- 239000000199 parathyroid hormone Substances 0.000 description 1
- 229960001319 parathyroid hormone Drugs 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000004258 retinal degeneration Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 229960002101 secretin Drugs 0.000 description 1
- OWMZNFCDEHGFEP-NFBCVYDUSA-N secretin human Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(N)=O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)C1=CC=CC=C1 OWMZNFCDEHGFEP-NFBCVYDUSA-N 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
- C07K14/723—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.以下のN末端アミノ酸配列 MTPQSLLQTT(配列番号:1) により特徴付けられる、Gタンパク質共役型受容体または該受容体の機能的 に同等な断片をコードする単離したポリヌクレオチド分子。 2.前記ポリヌクレオチド分子がヒト由来の約693アミノ酸長Gタンパク質共役 型受容体をコードする、請求項1に記載のポリヌクレオチド分子。 3.前記ポリヌクレオチド分子が、配列番号:2に記載されたものに実質的に相 当するアミノ酸配列を含むGタンパク質共役型受容体をコードする、請求項 2に記載のポリヌクレオチド分子。 4.前記ポリヌクレオチド分子が、配列番号:3または配列番号:4に示される ものと少なくとも75%の配列同一性を示すヌクレオチド配列または機能的に 同等な受容体断片をコードするその部分を含む、Gタンパク質共役型受容体 をコードする単離したポリヌクレオチド分子。 5.前記ポリヌクレオチド分子が、配列番号:3または配列番号:4に示される ものと少なくとも90%の配列同一性を示すヌクレオチド配列または機能的に 同等な受容体断片をコードするその部分を含む、請求項4に記載のポリヌク レオチド分子。 6.前記ポリヌクレオチド分子が、配列番号:3または配列番号:4に示される ものと少なくとも95%の配列同一性を示すヌクレオチド配列または機能的に 同等な受容体断片をコードするその部分を含む、請求項5に記載のポリヌク レオチド分子。 7.請求項1〜6のいずれか1項に記載のポリヌクレオチド分子を含むプラスミ ドまたは発現ベクター。 8.請求項1〜6のいずれか1項に記載のポリヌクレオチド分子を用いて形質転 換した宿主細胞。 9.前記細胞が哺乳動物または昆虫の細胞である、請求項8に記載の宿主細胞。 10.前記細胞がチャイニーズハムスター卵巣(CHO)細胞、ヒト胚腎(HEK) 293細胞または昆虫Sf9細胞である、請求項9に記載の宿主細胞。 11.前記細胞がGタンパク質共役型受容体または機能的に同等なその断片を前記 細胞上に発現する、請求項8〜10のいずれか1項に記載の宿主細胞。 12.以下のN末端アミノ酸配列: MTPQSLLQTT(配列番号:1) により特徴付けられる、実質的に純粋な形のGタンパク質共役型受容体また は該受容体の機能的に同等な断片。 13.前記受容体が約693アミノ酸からなるヒト受容体である、請求項12に記載の 受容体。 14.前記受容体が、配列番号:2に記載のものに実質的に相当するアミノ酸配列 を有する、請求項13に記載の受容体。 15.請求項12〜14のいずれか1項に記載のGタンパク質共役型受容体に特異的に 結合する抗体またはその断片。 16.請求項1〜6のいずれか1項に記載のポリヌクレオチド分子を用いて形質転 換された非ヒト動物。 17.請求項12〜14のいずれか1項に記載のGタンパク質共役型受容体または請求 項1〜6のいずれか1項に記載のDNA分子で形質転換されてこれを発現す る宿主細胞を、該受容体を活性化させることができる条件下において試験薬 と接触させること、および該受容体活性の増減を検出することを含む、Gタ ンパク質共役型受容体のアゴニストまたはアンタゴニスト作用物質を検出す るための方法。 18.10以上のヌクレオチドからなるヌクレオチド配列を含むオリゴヌクレオチド またはポリヌクレオチドプローブであって、該プローブが高ストリンジェン シー条件下において請求項1から6のいずれか1項に記載のポリヌクレオチ ド分子に特異的にハイブリダイズするようなヌクレオチド配列を含む、プロ ーブ。 19.mRNA分子の翻訳を妨げるために、請求項1から6のいずれか1項に記載のポ リヌクレオチド分子によりコードされるGタンパク質共役型受容体をコード するmRNA分子に特異的にハイブリダイズすることができるヌクレオ チド配列を含む、アンチセンスポリヌクレオチド分子。 20.ポリヌクレオチド分子の発現を可能にする条件下において、請求項8から11 のいずれか1項に記載の宿主細胞を培養すること、および任意で受容体また は機能的に同等なその断片を回収すること、を含む、請求項12〜14のいずれ か1項に記載のGタンパク質共役型受容体または機能的に同等なその断片を 産生する方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU9386 | 1988-07-20 | ||
AUPO9386A AUPO938697A0 (en) | 1997-09-24 | 1997-09-24 | Novel receptor |
PCT/AU1998/000805 WO1999015551A1 (en) | 1997-09-24 | 1998-09-24 | Novel receptor |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2001513653A true JP2001513653A (ja) | 2001-09-04 |
Family
ID=3803668
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP51834899A Ceased JP2001513653A (ja) | 1997-09-24 | 1998-09-24 | 新規な受容体 |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP0973800A4 (ja) |
JP (1) | JP2001513653A (ja) |
AU (1) | AUPO938697A0 (ja) |
CA (1) | CA2271700A1 (ja) |
WO (1) | WO1999015551A1 (ja) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6391311B1 (en) * | 1998-03-17 | 2002-05-21 | Genentech, Inc. | Polypeptides having homology to vascular endothelial cell growth factor and bone morphogenetic protein 1 |
US7279553B2 (en) * | 1998-05-13 | 2007-10-09 | Genentech, Inc. | PRO1083 polypeptides |
WO2000020590A2 (en) * | 1998-10-06 | 2000-04-13 | Incyte Pharmaceuticals, Inc. | G-protein coupled receptor proteins |
AU2162000A (en) * | 1998-12-10 | 2000-06-26 | Zymogenetics Inc. | Seven transmembrane domain receptor zsig56 |
EP1220912A2 (en) * | 1999-10-01 | 2002-07-10 | Lexicon Genetics Incorporated | Novel human membrane proteins |
AU2085901A (en) * | 1999-12-15 | 2001-06-25 | Zymogenetics Inc. | Human secretin-like receptor |
EP1280827A1 (en) * | 2000-05-03 | 2003-02-05 | AstraZeneca AB | Agonists/antagonists of the gpr56 receptor as appetite control agents |
WO2002034781A1 (en) * | 2000-10-20 | 2002-05-02 | Solvay Pharmaceuticals Gmbh | Human g-protein coupled diadenosine tetraphosphate receptor (ap4ar) |
-
1997
- 1997-09-24 AU AUPO9386A patent/AUPO938697A0/en not_active Abandoned
-
1998
- 1998-09-24 EP EP98946142A patent/EP0973800A4/en not_active Withdrawn
- 1998-09-24 WO PCT/AU1998/000805 patent/WO1999015551A1/en not_active Application Discontinuation
- 1998-09-24 CA CA002271700A patent/CA2271700A1/en not_active Abandoned
- 1998-09-24 JP JP51834899A patent/JP2001513653A/ja not_active Ceased
Also Published As
Publication number | Publication date |
---|---|
EP0973800A4 (en) | 2001-10-04 |
EP0973800A1 (en) | 2000-01-26 |
WO1999015551A1 (en) | 1999-04-01 |
AUPO938697A0 (en) | 1997-10-16 |
CA2271700A1 (en) | 1999-04-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6696257B1 (en) | G protein-coupled receptors from the rat and human | |
US20030157558A1 (en) | Novel guanosine triphosphate-binding protein-coupled receptors, genes thereof and production and use of the same | |
WO2003093444A2 (en) | Transporters and ion channels | |
US7510846B2 (en) | Assay employing human or rat GAL-R2 galanin receptor | |
JP2002531091A (ja) | Pth1rおよびpth3rレセプター | |
US7238780B2 (en) | G-protein coupled receptor | |
JP2001513653A (ja) | 新規な受容体 | |
JPH1084976A (ja) | 新規ヒトg−蛋白質結合レセプター | |
JP2003508026A (ja) | ヒトg−タンパク質共役型受容体 | |
Shepard et al. | Electrically silent potassium channel subunits from human lens epithelium | |
Loh et al. | Molecular characterization of a novel glycoprotein hormone G-protein-coupled receptor | |
KR19990064263A (ko) | 뉴로펩티드 y-y5 수용체 | |
US6750322B2 (en) | Guanosine triphosphate (GTP) binding protein-coupled receptor proteins | |
CA2435260A1 (en) | Receptors and membrane-associated proteins | |
WO2003016493A2 (en) | Transporters and ion channels | |
WO2000058462A1 (fr) | Nouvelles proteines de recepteur couplees aux proteines de liaison a la guanosine triphosphate (gtp), bg3 | |
US6682908B1 (en) | Mouse growth hormone secretagogue receptor | |
EP1463818A2 (en) | Transporters and ion channels | |
JP2002501723A (ja) | オーファンレセプター | |
EP0561496A2 (en) | cDNAs encoding the gastrin and CCK-B receptors | |
WO2000002918A1 (en) | Mouse growth hormone secretagogue receptor | |
Loh | Molecular characterization of a novel glycoprotein hormone receptor, GPR48 | |
US20030143670A1 (en) | DNA encoding SNORF44 receptor | |
WO2004013293A2 (en) | Transporters and ion channels |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20040108 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20050922 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080701 |
|
A313 | Final decision of rejection without a dissenting response from the applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A313 Effective date: 20081125 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20090217 |